1. Home
  2. LEE vs LIXT Comparison

LEE vs LIXT Comparison

Compare LEE & LIXT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Lee Enterprises Incorporated

LEE

Lee Enterprises Incorporated

HOLD

Current Price

$5.24

Market Cap

31.3M

ML Signal

HOLD

Logo Lixte Biotechnology Holdings Inc.

LIXT

Lixte Biotechnology Holdings Inc.

HOLD

Current Price

$2.90

Market Cap

25.4M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
LEE
LIXT
Founded
1890
2005
Country
United States
United States
Employees
N/A
N/A
Industry
Newspapers/Magazines
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
31.3M
25.4M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
LEE
LIXT
Price
$5.24
$2.90
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
88.4K
79.7K
Earning Date
02-05-2026
11-12-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$562,341,000.00
N/A
Revenue This Year
$5.48
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$3.34
$0.64
52 Week High
$15.15
$6.26

Technical Indicators

Market Signals
Indicator
LEE
LIXT
Relative Strength Index (RSI) 66.83 29.61
Support Level $4.60 $3.26
Resistance Level $5.33 $3.66
Average True Range (ATR) 0.43 0.29
MACD 0.07 -0.07
Stochastic Oscillator 78.74 1.30

Price Performance

Historical Comparison
LEE
LIXT

About LEE Lee Enterprises Incorporated

Lee Enterprises Inc is a local news publication company in the United States. It is a digital-first subscription business providing local markets with valuable, high-quality, trusted, intensely local news, information, advertising, and marketing services. The product portfolio of the company includes digital subscription platforms, daily, weekly, and monthly newspapers, and niche products, all delivering original local news and information as well as national and international news. The products offer digital and print editions, and content and advertising are available in real-time through the websites and mobile apps.

About LIXT Lixte Biotechnology Holdings Inc.

Lixte Biotechnology Holdings Inc is a biopharmaceutical company dedicated to improving patients' lives by developing a drug class called Protein Phosphatase 2A inhibitors. Its product pipeline is focused on inhibitors of protein phosphatase 2A, used in combination with cytotoxic agents and/or x-rays, immune checkpoint blockers, and other cancer therapies. The Company believes that inhibitors of protein phosphatases have therapeutic potential for a broad range of cancers. It focuses on the clinical development of a specific protein phosphatase inhibitor, referred to as LB-100, which has been shown to have clinical anti-cancer activity at doses that produce little or no toxicity.

Share on Social Networks: